Postby claudine » Sat Jul 18, 2020 9:33 am
Johnj, since you are KRAS mutated, has your oncologist mentioned Onvansertib? It’s new but fast tracked in the trials so I think oncologists can request it. It’s given in complement to Folfiri and Avastin and is specifically for KRAS MSS patients, and quite promising.
Another weapon in the arsenal, should lonsurf have too many side effects or not be as efficient as hoped.
Good luck to you and jep’s husband with the new treatments XXXXXXXX
Wife of Dx 04/18 (51 yo). MSS, KRAS G12A, no primary
Tumors: L4 04/18; left adrenal gland & small lung nodules 03/19
rectum 02/22 (pT3 pN0 stage 2A); L3 09/22
Surgeries: intestinal resect. 05/18 (no cancer - Crohn's); adrenalectomy 02/20
L3-L4-L5 fusion and corpectomy 05/20; LAR 04/22; ileo reversal 09/22
L2-L3 fusion and corpectomy 09/22
Treatments: EBRT 04/18; SBRT 02/19; Failed adjuvant Xelox ; Folfiri/Avastin 03/19 - 01/20
adjuvant chemorad (Xeloda) 06/22; SBRT 11/22; Xeloda/Avastin since 01/24